Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS)
- NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.
- 09/27/2024
|
Sharps Technology, Inc. Closes $3.5 Million Bridge Financing
- NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million.
- 09/24/2024
|
Sharps Technology, Inc. Announces $3.5 Million Bridge Financing
- NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million.
- 09/23/2024
|
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders' Meeting
- NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announced today that the Company has secured approval from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) to maintain its listing, subject to conditions outlined below.
- 09/12/2024
|
Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline
- Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company's continued growth.
- 07/09/2024
|
Nasdaq Surges Over 100 Points; Sharps Technology Shares Spike Higher
- U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Friday.
- 07/05/2024
|
What's Going On With Nano-Cap Medical Device-Focused Sharps Technology On Friday?
- Shares of Sharps Technology Inc STSS are trading higher on Friday, with a heavy session volume of 15.17 million.
- 07/05/2024
|
Sharps Technology Receives Purchase Orders for 1 Million SecureGard Syringes for 2024 Delivery
- Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies issues purchase orders for 1mL SecureGard ultra-low waste, smart safety syringes
- 07/03/2024
|
Sharps Technology Ships First Orders for Securegard Disposable Smart Safety Syringes to Strategic Distribution Partner in Colombia
- Orders for Sharps Securegard 1mL and 3mL syringes are on the water, introducing a line of competitively priced, low waste, smart safety syringes to the Colombian Healthcare System and the Latin American Market Orders for Sharps Securegard 1mL and 3mL syringes are on the water, introducing a line of competitively priced, low waste, smart safety syringes to the Colombian Healthcare System and the Latin American Market
- 06/17/2024
|
Join Sharps Technology's Exclusive Live Investor Webinar and Q&A Session on June 18
- NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is pleased to invite investors to a webinar on June 18, 2024, at 4:15 p.m. ET.
- 06/14/2024
|
Why Is Sharps Technology (STSS) Stock Up 21% Today?
- Sharps Technology (NASDAQ: STSS ) stock is up on Thursday after the medical device company announced a $30 million purchase order for its specialty copolymer prefillable syringes. Sharps Technology says this purchase order comes from Nephron Pharmaceuticals.
- 06/13/2024
|
Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility
- Signed PO secures first 12 months of syringe product orders against Sharps and Nephron's five-year, $200 million Syringe Sales Agreement.
- 06/13/2024
|
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (Nasdaq:SNGX) and Sharps Technology Inc. (Nasdaq:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET).
- 06/07/2024
|
Sharps Technology's SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.
- Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S.
- 05/31/2024
|
3 Penny Stocks Trading Abnormal Volume Today
- As the overall market trades just 1.5% away from its all-time high and up over 4% on the month, there has been a noticeable increase in risk appetite and speculation in small-cap penny stocks by retail investors. This surge in interest follows the meme mania experienced earlier in the month.
- 05/30/2024
|
Sharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.
- Sharps will strengthen its manufacturing capacity with a $35 million acquisition of assets, establishing the Company's position in the specialized copolymer prefillable syringe (PFS) system industry in the U.S.
- 05/30/2024
|
Sharps Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured Syringes
- Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chinese-manufactured syringes in November 2023, resulting in multiple recalls and warnings for these products during the first quarter of 2024, and has advised that healthcare facilities should use plastic syringes produced elsewhere.
- 05/28/2024
|
Why Is Sharps Technology (STSS) Stock Up 194% Today?
- Sharps Technology (NASDAQ: STSS ) stock is rocketing higher on Tuesday after the company announced a potential five-year purchase agreement with Nephron. This agreement has Nephron making Sharps Technology its exclusive pre-filled copolymer syringe manufacturer.
- 05/28/2024
|
Head-To-Head Analysis: NeuroMetrix (NASDAQ:NURO) & Sharps Technology (NASDAQ:STSS)
- NeuroMetrix (NASDAQ:NURO – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Profitability This table compares NeuroMetrix and Sharps Technology’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NeuroMetrix -151.51% -39.85% -37.08% Sharps Technology N/A -102.25% -72.97% Valuation and Earnings This table compares NeuroMetrix and Sharps Technology’s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroMetrix $5.90 million 1.38 -$6.53 million ($6.30) -0.64 Sharps Technology N/A N/A -$9.84 million N/A N/A NeuroMetrix has higher revenue and earnings than Sharps Technology. Analyst Recommendations This is a summary of current ratings for NeuroMetrix and Sharps Technology, as provided by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroMetrix 0 0 0 0 N/A Sharps Technology 0 0 0 0 N/A Volatility & Risk NeuroMetrix has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Insider & Institutional Ownership 19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by company insiders. Comparatively, 14.1% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Summary NeuroMetrix beats Sharps Technology on 6 of the 8 factors compared between the two stocks. About NeuroMetrix (Get Free Report) NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts. About Sharps Technology (Get Free Report) Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
- 05/20/2024
|
Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems
- Sharps and Roncadelle are Joining Forces to Sell and Distribute their Securegard, SAFER, and Sologard Lines of Disposable Smart Safety Syringes and Expand their Market Reach Around the Globe Sharps and Roncadelle are Joining Forces to Sell and Distribute their Securegard, SAFER, and Sologard Lines of Disposable Smart Safety Syringes and Expand their Market Reach Around the Globe
- 03/07/2024
|
Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems
- Sharps and Roncadelle are Joining Forces to Supply Drug Delivery Systems to the International HealthCare Market Through an Expanded Network of North American 3PL Distribution Partnerships Sharps and Roncadelle are Joining Forces to Supply Drug Delivery Systems to the International HealthCare Market Through an Expanded Network of North American 3PL Distribution Partnerships
- 02/16/2024
|
Sharps Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems
- Agreement would result in Sharps and Roncadelle Joining Forces to Access Global Healthcare Organizations Through More Than 30 Sales Partners worldwide Agreement would result in Sharps and Roncadelle Joining Forces to Access Global Healthcare Organizations Through More Than 30 Sales Partners worldwide
- 01/18/2024
|
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ: STSS)
- NEW YORK, NY / ACCESSWIRE / September 29, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry.
- 09/29/2023
|
Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private Placement
- NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors.
- 09/29/2023
|
Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
- ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET).
- 09/29/2023
|
Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year Purchase Agreement with Nephron Pharmaceuticals
- Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facil
- 09/28/2023
|
UPDATE - Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
- NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share is $0.64. The purchase price for the pre-funded warrants is identical to the purchase price for shares, less the exercise price of $0.001 per share.
- 09/27/2023
|
Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
- NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering.
- 09/27/2023
|
Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals
- $50 Million acquisition of InjectEZ strengthens manufacturing capacity and establishes Sharps' leading position in the specialized copolymer prefillable syringe system industry Signed term sheet providing for up to $75 Million in debt financing to be used for the acquisition Nephron commits to minimum orders of over $400 Million over 10 years; $30 Million in revenue the first year and subsequent minimum orders totaling over $45 Million in annual revenue through December of 2033 NEW YORK and WEST COLUMBIA, S.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Nephron Pharmaceuticals Corporation, (“Nephron”) a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron's InjectEZ specialty syringe manufacturing facility.
- 09/26/2023
|
Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales
- Key appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market
- 07/12/2023
|
Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
- The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
- 09/08/2022
|
What You Need to Know About Buying Penny Stocks in 2022
- Check these tips out for trading penny stocks in 2022 The post What You Need to Know About Buying Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 05/08/2022
|
